What are the emerging diagnostic technologies for rapid identification and susceptibility testing of Pseudomonas aeruginosa?

Oct 12, 2022 ... PAO1 and PA14 are common laboratory reference strains, modeling moderately and hyper-virulent phenotypes, respectively. Antibiotics with a novel mode of action will be needed to avoid cross resistance against currently used therapeutic agents. Importantly, antivirulence drugs are ... Some P. aeruginosa are becoming more resistant to even antibiotics of last resort, and are described as multidrug-resistant. Mar 22, 2024 ... FDA has completed their review of the rationale document titled, “Piperacillin-Tazobactam Breakpoints for Pseudomonas aeruginosa” (MR15, ... Multidrug efflux pumps are among the main Pseudomonas aeruginosa antibiotic-resistance determinants. Besides, efflux pumps are also involved in other ... Some types of Pseudomonas have developed resistance to carbapenems, and these bacteria are called carbapenem-resistant Pseudomonas aeruginosa (CRPA). Jun 25, 2022 ... Pseudomonas aeruginosa is a multi-drug resistance (MDR) opportunistic pathogens, causing acute or chronic infection in immunocompromised individuals. Sep 7, 2000 ... We conducted an epidemiologic and molecular investigation of endemic P. aeruginosa infection among infants in a neonatal intensive care unit. How is a pseudomonas infection treated? Antibiotics are the main treatment for a pseudomonas infection. It can be hard to find the right antibiotic because the ... Most pseudomonads known to cause disease in humans are associated with opportunistic infections. These include P aeruginosa, P fluorescens, P putida, P cepacia, ...